2-21033498-C-T
Variant summary
Our verdict is Likely benign. The variant received -3 ACMG points: 0P and 3B. BP4_ModerateBP6
The NM_000384.3(APOB):c.925G>A(p.Ala309Thr) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000268 in 1,613,926 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 14/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. A309S) has been classified as Uncertain significance.
Frequency
Consequence
NM_000384.3 missense
Scores
Clinical Significance
Conservation
Publications
- hypercholesterolemia, autosomal dominant, type BInheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Genomics England PanelApp, G2P, Labcorp Genetics (formerly Invitae), ClinGen, Ambry Genetics
- familial hypobetalipoproteinemia 1Inheritance: AR, AD, SD Classification: DEFINITIVE, STRONG Submitted by: PanelApp Australia, Labcorp Genetics (formerly Invitae), Genomics England PanelApp, ClinGen
- homozygous familial hypercholesterolemiaInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Likely_benign. The variant received -3 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| APOB | NM_000384.3 | c.925G>A | p.Ala309Thr | missense_variant | Exon 9 of 29 | ENST00000233242.5 | NP_000375.3 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| APOB | ENST00000233242.5 | c.925G>A | p.Ala309Thr | missense_variant | Exon 9 of 29 | 1 | NM_000384.3 | ENSP00000233242.1 |
Frequencies
GnomAD3 genomes AF: 0.000224 AC: 34AN: 152100Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.000211 AC: 53AN: 251452 AF XY: 0.000191 show subpopulations
GnomAD4 exome AF: 0.000273 AC: 399AN: 1461826Hom.: 0 Cov.: 32 AF XY: 0.000246 AC XY: 179AN XY: 727220 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.000224 AC: 34AN: 152100Hom.: 0 Cov.: 32 AF XY: 0.000202 AC XY: 15AN XY: 74276 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
not provided Uncertain:2
- -
The APOB c.925G>A (p.Ala309Thr) variant has not been reported in individuals with APOB-related conditions in the published literature. The frequency of this variant in the general population, 0.00073 (19/26134 chromosomes in Swedish subpopulation (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is higher than would generally be expected for pathogenic variants in this gene. Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is benign. Based on the available information, we are unable to determine the clinical significance of this variant. -
Hypercholesterolemia, autosomal dominant, type B;C4551990:Familial hypobetalipoproteinemia 1 Uncertain:1Benign:1
- -
- -
not specified Uncertain:1
DNA sequence analysis of the APOB gene demonstrated a sequence change, c.925G>A, in exon 9 that results in an amino acid change, p.Ala309Thr. This sequence change has been described in gnomAD with a low population frequency of 0.022% (dbSNP rs141888564). The p.Ala309Thr change affects a moderately conserved amino acid residue located in a domain of the APOB protein that is known to be functional. The p.Ala309Thr substitution appears to be benign using several in-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL). This sequence change does not appear to have been previously described in patients with APOB-related disorders. Due to the lack of sufficient evidences, the clinical significance of the p.Ala309Thr change remains unknown at this time. -
Cardiovascular phenotype Benign:1
This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at